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Abstract: Cholangiocarcinoma (CCA) is a genetically and histologically complex disease with
a highly dismal prognosis. A deeper understanding of the underlying cellular and molecular
mechanisms of human CCA will increase our current knowledge of the disease and expedite
the eventual development of novel therapeutic strategies for this fatal cancer. This endeavor is
effectively supported by genetic mouse models, which serve as sophisticated tools to systematically
investigate CCA pathobiology and treatment response. These in vivo models feature many of the
genetic alterations found in humans, recapitulate multiple hallmarks of cholangiocarcinogenesis
(encompassing cell transformation, preneoplastic lesions, established tumors and metastatic disease)
and provide an ideal experimental setting to study the interplay between tumor cells and the
surrounding stroma. This review is intended to serve as a compendium of CCA mouse models,
including traditional transgenic models but also genetically flexible approaches based on either the
direct introduction of DNA into liver cells or transplantation of pre-malignant cells, and is meant as a
resource for CCA researchers to aid in the selection of the most appropriate in vivo model system.
Keywords: cholangiocarcinoma; biliary tract; hydrodynamic injection; genetically-engineered mice;
in vivo models
1. Introduction
Cholangiocarcinoma (CCA) is the most prevalent biliary neoplasm and the second most frequent
liver tumor after hepatocellular carcinoma (HCC), accounting for 10–20% of cancer-related deaths due
to hepatobiliary malignancies [1,2]. CCA involves a heterogeneous group of cancers arising from the
biliary tree that can be classified based on their anatomical location as intrahepatic (iCCA), perihiliar
(pCCA) and distal (dCCA) [3,4]. Biliary inflammation is the common denominator of several risk
factors identified thus far, such as primary sclerosing cholangitis, infestation with liver flukes, hepatitis
C or B virus infection, chronic alcohol abuse, and non-alcoholic steatohepatitis. Most CCAs, however,
are considered sporadic and arise in the absence of evident risk factors.
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Surgical resection remains the only potentially curative therapeutic option, but only one-third
of patients qualify for surgery at the time of diagnosis and early recurrence worsens the prognosis.
Since the disease frequently remains clinically silent for a long time, most patients are bound to receive
palliative treatments from initial diagnosis onwards. Based on the results from the ABC-02 trial,
the standard chemotherapeutic regimen consists of gemcitabine in combination with cisplatin, leading
to a median overall survival of 11.7 months with a median progression-free survival of 8 months [5].
Retrospective analyses regarding the use of second line treatments have been inconclusive and, thus far,
no second line treatment recommendations exist, further emphasizing the imperative need for novel
and more effective therapeutic strategies.
The molecular landscape of cholangiocarcinoma is heterogeneous and segregates with the
anatomical location as well as the underlying risk factors. Based on the results from recent sequencing
studies, an extensive catalogue of genetic alterations exists, including oncogenic activation of KRAS, or
inactivating mutations in tumor suppressor genes (TSGs) such as TP53, CDKN2A/B, SMAD4 and PTEN,
as well as in DNA repair genes (e.g., BRCA) and epigenetic modifiers such as ARID1A. Notably, in about
30–40% of CCA patients, molecularly targetable alterations exist, indicating that precision medicine
may be beneficial in a considerable subset of biliary tract cancers. Indeed, several of such “targeted”
agents have already been tested within the framework of clinical trials, including FGFR inhibitors
in patients with FGFR2 fusions, IDH inhibitors in patients with IDH1/2 mutations, and BRAF/MEK
inhibitors in patients with activating BRAF mutations. Despite the increasing number of clinical trials,
the early positive signals for precision medicine and an expanding “toolbox” for the treatment of CCA
patients, we are still lacking a “deeper” understanding of those complex mechanisms that lead to the
development of biliary cancer and determine the response or resistance to therapy.
As the genetic annotation of human cancer evolved, a plethora of genetically engineered murine
models of cancer have been developed, which have since then served as pre-clinical platforms that
allow us to study the disease in the context of a clinically relevant, intact microenvironment. With the
increasing clinical and scientific recognition of biliary tract cancers, a repertoire of murine model
systems for CCA has been developed in recent years and is now at our disposal to choose from.
Considering the heterogeneity of the disease and the vast array of open questions regarding CCA
pathophysiology, it is highly unlikely, though, that one single model will serve as “the ultimate”,
universal pre-clinical tool. In this review, we will discuss a selection of murine models that have the
potential to accelerate CCA research, expand our current knowledge about this cancer and, eventually,
unveil novel opportunities to build better treatment strategies.
2. Genetic Mouse Models of CCA
Various genetic mouse models that portray the ample catalogue of mutations found in human CCA
have been developed for the characterization of different stages of cholangiocarcinogenesis, ranging
from the neoplastic transformation of normal liver or biliary cells to CCA progression and metastasis.
In general, these models are based on three distinct genetic approaches: (1) somatic gene transfer
into adult liver cells by hydrodynamic tail vein injection, liver electroporation, or adeno-associated
virus (AAV) in vivo transduction (2) the manipulation of mouse embryonic stem cells to generate
genetically-engineered mice, or (3) transplantation of pre-malignant cells, such as genetically engineered
fetal liver cells or biliary organoids.
3. Somatic Gene Transfer Models
3.1. Hydrodynamic Tail Vein Injection (HTVI) Models
HTVI models are based on the delivery of plasmid DNA into hepatocytes by means of high-volume
injection: controlled hydrodynamic pressure in capillaries enhances the permeability of endothelial
and parenchymal cells, allowing DNA to enter the cells through the transient opening of “pores” in
the plasma membrane (reviewed in [6]). Through the incorporation of the Sleeping Beauty transposon
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toolbox to the hydrodynamic injection technique, stable integration of transgenes can be achieved in
several tissues [7,8]. Notably, the liver is particularly prone to plasmid DNA incorporation and HTVI
efficiently targets up to 10% of liver cells. Therefore, several groups have adopted this technology for
the generation of mouse models of liver carcinogenesis based on the introduction of genetic alterations
found in the human counterparts [9].
HTVI models pose a series of advantages for in vivo studies. First, since only a fraction
of hepatocytes is targeted by HTVI, normal and transformed cells coexist in the autochthonous
environment, thus mimicking the human setting. Second, given that recipient mice are 6–8 weeks old,
tumors develop in an adult organism, as is most commonly the case in humans. Third, many HTVI
models form tumors very rapidly (1–2 months), thereby accelerating experimental readout. The main
limitation of this method is the fact that HTVI delivers genes exclusively into hepatocytes of the
pericentral region (zone 3 of the liver acinus). Therefore, a transdifferentiation stimulus, likely induced
by the respective transgenic driver, is needed to facilitate CCA-like histologies, and studies aimed at
investigating the role of hepatic stem cells or biliary epithelial cells to CCA carcinogenesis are not
possible using this approach. Furthermore, all HTVI studies focus on CCA initiation, i.e., to understand
the role of CCA-relevant genes in cancer formation, but not in progression and metastasis. Lastly,
in contrast to what is frequently observed in the human situation, tumors in conventional HTVI models
develop in the absence of an inflammatory microenvironment, which limits their applicability for
studies of tumor–stroma crosstalk. Table 1 summarizes the HTVI models of CCA described to date,
with some of the most representative and/or time-efficient models discussed in more detail.
Table 1. Genetic models based on liver transgene delivery. Summary of CCA models based on
transgene delivery via HTVI or liver electroporation. iCCA: intrahepatic CCA; eCCA: extrahepatic
CCA; HCC: hepatocellular carcinoma.
Somatic Gene Transfer Delivery Models
Transgene and Mouse Genetic Background Key Features Reference
NRasV12 in Ink4A/Arf−/− mice Development of mixed HCC/iCCA 4–6 weeks after HTVI [10]
Yap and PI3KCA in wt mice
HCC (~40%), CCA (~10%), and mixed HCC/iCCA (~50%)
formation. iCCAs cover ~80% of the liver parenchyma
within 12–13 weeks post-HTVI
[11]
NICD1 in wt mice HTVI induces formation of cystic cholangiocellular tumorsresembling human biliary cystadenomas by 20 weeks [12]
NICD1 and AKT in wt mice
Quick formation of iCCA (4.5 weeks after HTVI) with signs
of malignancy such as high content of mitotic figures,
necrosis and invasion of the liver parenchyma
[12]
MyrAKT and YAP (S127A) in wt mice Quick (3 weeks post-HTVI) model of iCCA [13]
MyrAKT and NRAS (V12D) in wt mice Quick (3 weeks post-HTVI) model of mixed HCC/iCCA [14–16]
NICD in KrasLSL-G12D mice
Tumors of ductal and cystic morphology with variable
amount of desmoplastic stroma invading the surrounding
hepatocellular parenchyma 8 weeks after HTVI
[17]
Overexpression of Jag1 and AKT in wt mice Tumors of solid, ductular or cystic differentiation with somestroma development 8 weeks after HTVI. Exclusively iCCA [18]
NICD, YAP and Tp53 shRNA
HCCs or iCCAs form 6 weeks post-HTVI in response to Wnt
and Notch signaling respectively Nestin-positive
progenitor-like cells (from de-differentiated mature
hepatocytes) upon Tp53 loss
[19]
Myc and Nras or Myc and AKT
HTVI delivery induces HCC, while delivery of the same
oncogenes by electroporation forms stroma-rich iCCA (both
by models develop by 4 weeks after transgene delivery)
[20]
Cas9, Cre and sgRNAs in KrasLSL-G12D/+mice
Formation of HCC and iCCA 20–30 weeks after delivery
via HTVI [21]
Cas9 and sgRNAs to Pten and Tp53 Liver tumors featuring bile duct differentiation markers(CK19 positive) by 12 weeks post-HTVI [22]
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Table 1. Cont.
Somatic Gene Transfer Delivery Models
Transgene and Mouse Genetic Background Key Features Reference
AKT and YAP plus IL-33 intraperitoneal
injection
Overexpression in biliary cells induces CCA formation along
the biliary system 10 weeks after HTVI. IL-33 increases
penetrance. Likely technically adaptable for
eCCA formation.
[23]
KRASG12V in Tp53f/f
Quick (3–5 weeks) model based on liver electroporation of
KRAS (G12V) induces single nodule iCCA formation [24]
3.1.1. RAS-Driven HTVI Models
In 2005, the Largaespada’s lab provided the proof-of-concept that transposon technology can
be used to study liver tumorigenesis [10]. In the first example of an HTVI liver cancer model,
exogenous expression of NRAS oncogene (G12V) in Arf−/− mice gave rise to an early onset of multiple
nodular tumors 4 to 6 weeks after transfection. Tumor latency doubled in heterozygous Arf+/−
mice, highlighting the importance of the genetic background of recipient mice in liver carcinogenesis.
Importantly, both HCC- and iCCA-like tumors arose in this model. Thus, the application of this liver
cancer model to exclusively study CCA pathobiology is limited.
Another HTVI-based study modeling the consequences of RAS-driven carcinogenesis was later
described by Zhang et al. Here, hydrodynamic injection of NRAS (G12V) and a constitutively active
form ofAKT (myrAKT) also yielded HCC and iCCA in mice 3 to 4 weeks after injection [14]. Interestingly,
a latter version of the model incorporated the genetic ablation of FASN, the master regulator of fatty
acid synthesis, whose expression is upregulated in human HCC samples but is frequently low in human
iCCA specimens. Upon administration of a Cre recombinase transgene simultaneously with NRAS
and AKT in Fasnflox/flox mice, developing tumors exhibited nearly exclusively iCCA differentiation,
highlighting the dependency of HCC—but not CCA—on de novo lipid synthesis [15].
3.1.2. NOTCH-Driven HTVI Models
One of the most rapid models of iCCA, which displays human CCA features such as high mitotic
activity, invasion of the surrounding liver parenchyma and necrosis, was reported in 2012. Based
on the frequent activation of NOTCH signaling found in human CCA, Fan et al. overexpressed
the intracellular domain of the NOTCH1 receptor (NICD) that shuttles from the membrane to the
nucleus to function as a pro-oncogenic transcriptional regulator. Single administration of NICD
transgene yielded CCA-like lesions exhibiting initial features of malignant transformation with a
latency of 20 weeks. Notably, concomitant transfection of NICD and AKT significantly accelerated
tumor development and led to formation of similar lesions with a latency of only 3.5 weeks that
progressed rapidly and occupied most of the liver parenchyma by 5 weeks [12]. Paralleling this
approach, transposon-based delivery of NICD and Cre-recombinase into genetically engineered mice
harboring the latent mutant Kras allele (KrasLSL-G12D) gave rise to liver tumors closely resembling
human CCA by 8 weeks post-transfection [17].
Upstream activation of NOTCH signaling can occur through the NOTCH ligand JAG1, which is
frequently upregulated in human CCA. Further supporting the decisive effects of NOTCH signaling
on cholangiocarcinogenesis, concomitant delivery of myrAKT1 together with JAG1 induces exclusively
iCCA formation, but not HCCs, by 8 weeks post-transfection [18].
A conceptually similar HTVI model took advantage of Yes-associated protein (YAP) overexpression.
YAP, a major downstream effector of Hippo-signaling, is considered to act as an oncogenic driver
in HCC and is also active in CCA [25]. Notably, YAP can positively regulate JAG1 expression [26],
providing a direct link to NOTCH signaling. Concomitant YAP and myrAKT transgene overexpression
led to activation of PI3K and RAS signaling, as well as an enhanced activity of the glycolytic pathway,
resulting in early iCCA formation within 3 weeks post-transfection and death of tumor-bearing mice
between 5.5 and 7.5 weeks. MTORC1 and mTORC2 are key downstream signaling components of
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AKT activation. Notably, while knockdown of mTORC1 significantly delayed tumor development,
genetic abrogation of mTORC2 not only delayed tumor onset, but also led to the development of tumor
lesions with hepatocellular -instead of cholangiocellular- differentiation [13].
As a second transposon-based HTVI model that featured YAP as a co-oncogenic driver, Li et al.
simultaneously delivered active-mutant forms of YAP (S127A) and PIK3CA (H1047R) into the mouse
liver, which resulted in the formation of liver tumors by approximately 12 to 13 weeks post-delivery.
In this model, tumor histology ranged from HCC (40%) and iCCA (10%), to mixed HCC/iCCA
(50%) [11]. Overall, the differences observed through overexpression of distinct elements within the
same signaling pathways reinforce the idea that a precise selection of transgenes is critical to steer the
development of appropriate HTVI models of CCA.
As a note of caution concerning the generalization of the reported latencies and histological
presentations, it cannot be excluded that tumor kinetics as well as histological presentation may, in part,
be dependent on the strain background and/or the gender of the “recipient” mouse.
3.1.3. CRISPR-Cas9-Based HTVI Approaches
In recent years, the genome-editing field has been extraordinarily transformed by the
bacterial RNA-guided clustered regularly interspaced palindromic repeat (CRISPR)-Cas9 system.
The CRISPR-Cas9 technology provides an efficient method for somatic gene editing of cancer-related
genes, both to generate functional knockouts (by the introduction of insertion or deletions-indels-in
specific genes) and to recreate driver mutations (by homology-directed repair) [27]. Pioneering work
by Xu et al. in 2014 illustrated that HTVI and CRISPR-Cas9 approaches could be successfully combined
for the study of intrahepatic tumors. Hydrodynamic administration of single guide RNAs (sgRNAs)
to target the TSGs Tp53 and Pten in wild-type FVB mice originated tumors of biliary differentiation
3 months after injection, faithfully recapitulating the liver lesions found in adeno-Cre-activated,
Tp53flox/flox; Ptenflox/flox mice [22].
One step further, the Rad lab took advantage of the CRISPR-Cas9 technology to perform a
multiplexed in vivo mutagenesis screen in order to identify biologically relevant TSGs involved in liver
cancer formation. A pool of 10 sgRNAs was injected together with a Cre recombinase transgene into
Alb-Cre; KrasLSL-G12D/+ mice, resulting in the formation of multifocal liver tumors of HCC and iCCA
histology 20 to 30 weeks after injection. Next generation sequencing (NGS) and comparative genomic
hybridization (CGH) detected no off-target effects in CRISPR-Cas9 induced liver tumors, highlighting
the accuracy of the gene editing strategy [21]. Given the wealth of genomic information from NGS
efforts, this study provides the experimental platform to quickly and efficiently screen biological
functions of newly identified CCA-related gene sets. Collectively, these two studies demonstrate that
HTVI and CRISPR-Cas9 approaches are complementary tools for the development and investigation
of CCA genetic models.
3.2. Liver Electroporation Models
Liver electroporation is an alternative technique for efficient hepatic gene delivery. Following
laparotomy, the liver is exposed, plasmids are injected into the parenchyma, and an electric pulse is
applied at the injection site. In contrast to HTVI approaches, which generally lead to the development
of multiple tumor nodules across the liver, liver electroporation generates mostly focal tumors at the
site of the electroporation.
A pioneer study by Gurlevik et al. demonstrated that Sleeping Beauty-mediated expression of
KrasG12V in p53f/f mice efficiently leads to iCCA development through the transdifferentiation of
hepatocytes. Additionally, this study highlighted the utility of the model to address adjuvant treatment
strategies after R0 resection [24].
More recently, in 2018, Seehawer et al. reported significant differences in the histology of liver
tumors formed when identical sets of oncogenes were introduced into hepatocytes by HTVI or liver
electroporation techniques. Co-expression of oncogenic Myc and NrasG12V, or Myc and AKT1 gave rise
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to multifocal liver carcinomas with HCC histology when introduced using HTVI, whereas, upon liver
electroporation, the same combination of oncogenes resulted in focal iCCA or combined iCCA–HCC
development. The authors went on to show that the surrounding hepatic microenvironment determines
the cell fate of liver tumors, revealing that, in transformed hepatocytes containing the same oncogenic
drivers, neighboring hepatocytes undergoing apoptosis induce the formation of HCC, while surrounding
necroptotic hepatocytes determine CCA outgrowth [20]. Thus, this study highlights the importance
of epigenetic cues from the tumor microenvironment in shaping the “phenotypic” differentiation of
liver tumors.
3.3. Intrabiliary Transfection of DNA
As discussed earlier, the development of new CCA models based on the HTVI as well as the liver
electroporation approach is compromised by the delivery of transgenes into hepatocytes, but not into
cholangiocytes. To circumvent this limitation, a novel model that facilitates the direct transfection of
biliary cells by intrabiliary injection coupled with lobar bile duct ligation was recently described by
Yamada et al. Introduction of AKT and YAP transgenes into biliary cells led to CCA development
in 20% of mice 10 weeks after in vivo transfection. Penetrance of tumor development could be
further increased to 72% through an IL-6 dependent mechanism upon intraperitoneal injection of the
biliary mitogen IL-33 [23]. The authors emphasized that tumor formation is not restricted to specific
locations within the biliary tree. Therefore, despite photographs from the publication suggesting
that most tumors arose as intrahepatic CCA, it appears likely that the approach could be adapted
to generate extrahepatic CCAs (eCCAs). Although technically challenging, this model offers new
opportunities for the generation of CCA mouse models by transposon-based gene delivery to the biliary
epithelium and, considering the IL6-dependent increase in tumor formation, somewhat recapitulates
the tumor-promoting role of inflammatory cues from the microenvironment.
4. Genetically Engineered Mouse (GEM) Models
GEM models are widely considered the most sophisticated animal models of human cancer. In
these autochthonous cancer models, tumor initiation occurs de novo under the tight control of specific
genetic modifications [28,29]. To date, multiple GEM models exist that faithfully recapitulate many
histopathological features of human cancers, from early transformation stages to metastasis. Moreover,
GEM models share molecular features with human cancers, as already illustrated in pioneering studies
based on cross-species comparison analyses [30–32]. Since then, almost any GEMs, including those
representative of CCA, have been investigated for their cellular and molecular similarities with their
human cancer counterpart. For these reasons, GEM models have been incorporated as in vivo platforms
for the rationale testing of standard-of-care chemotherapies and/or novel targeted agents [33].
GEM models of CCA developed to date incorporate many of the frequent oncogenic alterations
found in humans [34–39], thus tightly mirroring the molecular events driving cholangiocarcinogenesis.
A key advantage of these models is the development of tumors within the context of a complex organism.
Additionally, the spectrum of preneoplastic, early and late tumor stages (including metastasis) in a
highly reproducible setting enables the interrogation of critical aspects of carcinogenesis. However,
the generation of new GEM strains requires complex and time-consuming breeding strategies, and tumor
latency is relatively long in most cases, which translates into a significant economical investment. Unlike
in humans, expression of the respective genetic alterations already occurs during embryogenesis in most
non-inducible GEM models, although newly developed mouse strains aid to circumvent this problem.
For instance, the incorporation of tamoxifen inducible, organ-specific Cre-recombinase-encoding
alleles allows activation of latent alleles on demand in adult organisms. Further, hepatocyte-specific
activation/incorporation of transgenes in GEM models can be easily achieved through incorporation
of in vivo transfection techniques (HTVI and/or electroporation, described above), but also by using
adeno-associated-virus-based AAV8 vectors. Intravenous injection of AAV8 vectors achieves efficient
transgene delivery to hepatocytes, and additional specificity can be secured by using liver-specific
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promoters to drive transgene expression. Beyond the relative organ specificity, the use of endogenous
promoters to drive transgene expression may more closely recapitulate physiological expression levels
of the transgene in the host organism. Table 2 provides a summary of CCA GEM models reported to
date, with a more detailed description of some key approaches found below.
Table 2. Genetically engineered mice (GEM) and GEM-derived models. Summary of GEM models
and additional mouse models developed based on existing GEM. iCCA: intrahepatic CCA; eCCA:
extrahepatic CCA; HCC: hepatocellular carcinoma.
GEM and GEM-Derived Models
Genetic Strategy Key Features Reference
Alb-Cre, Smad4flox/flox, Ptenflox/flox
Liver progenitor cells (LPCs) iCCA development
involving a multistep sequence including hyperplasia,
dysplasia, carcinoma in situ and well-established CCA.
Tumor latency: 4–7 months
[40]
AhCreERT, KrasV12/+, Ptenflox/flox
Oncogenic events in biliary epithelium yield multifocal
non-invasive papillary neoplasms in the intrahepatic
biliary tract involving both major interlobular bile ducts
and small bile duct radicles in portal tracts. Mice survive
up to 43 days
[41]
Alb-Cre, KrasLSL-G12D/+, Ptenflox/flox
Highly invasive and desmoplastic CCA originated from
LPCs, with a glandular morphology that resembles
well-differentiated human CCA. Tumors form by 4 weeks
[42,43]
Alfp-Cre; Tp53flox/flox
Loss of p53 in LPCs leads to formation of advanced HCC
and iCCA. Tumor formation in 14–20-month-old mice [44]
Alb-Cre; KrasLSL-G12D/+;
Tp53flox/flox
Tumors of iCCA (66%), HCC (17%) and HCC/iCCA
(17%) histology. iCCA with multistage progression
including stroma-rich tumors, premalignant biliary
lesions (IPNB and VMC) and metastasis. Tumors form as
early as 9 weeks
[45]
Sox9-CreERT2+; KrasLSL-G12D/+,
Tp53flox/flox
Development of iCCA tumors accompanied by adjacent
extensive ductular reactions and desmoplasia, as well as
areas resembling biliary intraepithelial neoplasia (BIN).
Tumor latency: 30 weeks
[46]
KrasLSL-G12D/+; Tp53flox/flox
Mice infected with an adeno-associated virus expressing
Cre (AAV-TBG-Cre) develop iCCA (40%), HCC (40%),
mixed HCC/iCCA (20%). Tumors form between 12- and
66-weeks post-injection
[46]
Alb-Cre; KrasLSL-G12D/+;
Fbxw7LSL-R468C/LSL-R468C
Dysplastic dust-like structures surrounded by fibrosis (at
8 months, some heterozygous Fbxw7LSL-R468C mice show
bile duct dilation and hyperplasia).
[47]
Alb-Cre; IDH2LSL-R172K;
KrasLSL-G12D
All mice develop multifocal liver masses of iCCA
histology. Tumor latency: 33–58 weeks [48]
Alb-Cre; NotchICD
Transplantation of liver cells from 8 months-old mice in
immunodeficient animals produces iCCA, likely derived
from progenitor cells. Tumor latency: 8 months
[49]
Alb-Cre; Tp53flox/flox; NotchICD
iCCA with abortive glandular pattern (moderate to high
pleomorphic nuclei with some atypical mitoses)
developed along with a dense fibrous tissue with
inflammatory cells. Tumors form by 6 months
[50]
Alb-Cre; Hspd1flox/flox
Lesions of cholangiocellular histology, characterized by
irregular glands, loss of polarity, multilayering of cells,
and frequent mitosis resembling human BIN, form by
4–6 weeks
[51]
K19CreER; KrasLSL-G12D/+;
Tgfβr2flox/flox and Cdh1flox/flox
Swollen gallbladder including invasive periductal
infiltrating type eCCA metastasizing to lymphatic
vessels and a prominently thickened EHBD wall. Mice
die at 4 weeks of age
[52]
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Table 2. Cont.
GEM-based allograft models
Genetic Strategy Key Features Reference
Bipotent liver progenitor cells
(LPCs) from Alb-Cre; KrasLSL-G12D;
Tp53LSL-R172H/flox mice +/−
FIG-ROS fusion
Implanted LPCs give rise to liver tumors with advanced
iCCA features. Median overall survival of Alb-Cre;
KrasLSL-G12D; Tp53LSL-R172H/flox tumor-bearing mice:
79 days
[53]
Bipotent or cholangiocytic
progenitor cells or hepatocytes
from Tp53−/− mice
Tumors with mixed hepatocytic and cholangiocytic
differentiation embedded in a prominent stroma. Tumors
form between 30 and 120 days after cell inoculation
[44]
Adult liver organoids from
KrasLSL-G12D; Tp53flox/flox mice
after Cre-activation in vitro
Kras driven tumors lead to CCA formation, while
expression of c-Myc in wild-type organoids drives HCC
formation. Tumor latency for Cre- activated KrasLSL-G12D
Tp53flox/flox: 6–8 weeks
[54]
Carcinogen-treated GEM models
Alb-CreERT2; R26RlacZ/+ and
Ck19-CreERT2; R26RlacZ/+ mice
treated with TAA
Liver cirrhosis containing cells with the typical histology
of iCCA [55]
Ck19-CreERT/eYFP; Tp53flox/flox mice
treated with TAA
Formation of multifocal invasive iCCA. Tumors appear
after 26 weeks [56]
Tp53−/− mice treated with CCl4 Development of injury/necrosis, proliferation andfibrosis in bile duct after 4 months of treatment [57]
4.1. Loss of Smad4 and Pten Tumor Suppressor Genes
In 2006, Xu et al. developed the first GEM model of CCA. Combined ablation of liver-specific Pten
and Smad4, two mutations commonly found in human CCA [34–36], was obtained by crossing mice
harboring the conditional alleles for each TSG to the Albumin Cre (Alb-Cre) strain [40]. The Alb-Cre
strain allows recombination of the loxP sites in adult hepatocytes as well as in liver precursor cells
of hepatocytes and cholangiocytes during embryonic development [58]. In the Alb-Cre; Smad4flox/flox;
Ptenflox/flox model, hyperplastic foci arose from bile ducts at 2 months, and all mice developed iCCA
between 4 and 7 months of age. Thus, the model preserves the gradual progression from bile duct
hyperplasia and dysplasia to carcinoma in situ and invasive CCA that is frequently seen in the human
situation. Similar to HTVI models, activation of the PI3K-AKT-mTOR pathway led to the expected
phosphorylation of downstream targets, such as AKT, FOXO1, mTOR and GSK3β. Additionally,
hyperactivation of p-ERK and overexpression of cyclin D1 was observed. Finally, the authors showed
a reciprocal regulation of Pten and Smad4 to maintain an expression balance to suppress CCA,
thus highlighting the importance of the dual inhibition during CCA development in this model.
4.2. Simultaneous Activation of Kras and Deletion of Tp53
KRAS and TP53 mutations are two of the most frequent genetic events in human CCA with
prognostic implications for patients [37,39]. In 2012, pioneering studies from the Hezel lab reported the
first GEM model with combined Kras activation and Tp53 deletion [45]. In this model, KrasLSL-G12D/+;
Tp53flox/flox mice were bred to the Alb-Cre mouse strain. Liver tumors developed with full penetrance
in 9-week old mice, which succumbed to the disease with a mean survival of 19 weeks. Two thirds of
the tumors histologically resembled stroma-rich iCCAs, while the remaining mice developed mixed
HCC/iCCA or HCC at a similar frequency (17% each). The presence of premalignant biliary lesions
(intraductal papillary neoplasms -IPNB- and Von Meyenburg complexes -VMC-), indicated that in
this model tumors gradually evolve in a stepwise process that phenocopies the human situation,
culminating in the progression to invasive carcinoma and the potential to metastasize to distal organs.
As Albumin-Cre is already active during embryonic development in bipotential hepatic
progenitors, the cell of origin for iCCA formation in response to activation of Kras and Tp53 remained
unclear in this model. To further interrogate whether, in an adult organism, hepatocytes and/or
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cholangiocytes are amenable to Kras/p53 driven malignant transformation, the authors either directed
expression of Cre-recombinase towards the biliary compartment by breeding the tamoxifen-inducible,
Sox9-CreERT2+ allele into KrasLSL-G12D/+; Tp53flox/flox mice, or injected KrasLSL-G12D/+; Tp53flox/flox mice
with an adeno-associated vector expressing Cre-recombinase under the control of the hepatocyte-specific
thyroid-binding globulin promoter (AAV8-TBG-Cre) [59].
AAV-mediated expression of KrasG12D and loss of Tp53 in the adult hepatocyte was only
sufficient to drive tumorigenesis in this model when combined with an inflammatory stimulus by
co-administration of DDC-diet, leading to development of iCCA, but also HCC with a similar incidence,
as well as mixed iCCA/HCC tumors. In contrast, more rapid and mostly iCCA development was
observed without an additional inflammatory stimulus when the transgenes were activated in the
adult ductal compartment upon expression of SOX9-driven Cre-recombinase. Notably, evidence of
tumors developing through pre-neoplastic stages was only found in the Sox-9 approach, but not upon
DDC treatment [46].
In line with previous reports (e.g., [60]), these results confirm the functional role of Kras and
Tp53 in CCA and highlight the influence of liver inflammation on liver cancer formation by priming
hepatocytes for oncogenic transformation.
4.3. Concurrent Activation of Kras and Abrogation of Pten
A third model incorporating oncogenic Kras was reported by Ikenoue et al. in 2016. Expression of
mutantKras and concomitant deletion of the TSG Ptenwas targeted to liver cells using theAlb-Cremouse
strain. Active KrasG12D synergized with homozygous Pten ablation to form multifocal, stroma-rich
intrahepatic iCCA. On average, early hyperplastic biliary foci were detected around four weeks after
birth, and mice died after 46 days, making the model one of the fastest CCA GEM models described
to date using the Alb-Cre strain [42]. No metastatic lesions were described in this model. Notably,
the authors reported that Kras activation in combination with heterozygous Pten deletion developed
liver tumors with both hepatocyte and cholangiocyte differentiation, starting at 6 months of age,
indicating a dosage-effect of Pten expression. Paralleling the approach by Hill et al. [46], the authors
used two additional tamoxifen-regulatable GEM, Alb-CreERT2+ or K19CreERT/+ to activate Kras and
delete Pten expression in the adult organism selectively in hepatocytes or cholangiocytes, respectively.
However, in this particular model, no inflammatory additional stimulus was introduced. Interestingly,
administration of tamoxifen to adult, 8-week old Alb-CreERT2+; KrasLSL-G12D; Ptenflox/flox mice lead to
the development of HCC and HCC-precursor lesions, but not iCCA, whereas early postnatal tamoxifen
injection on day 10 resulted in iCCA. Notably, lineage tracing revealed that, on postnatal day 10,
Alb-Cre was still active in biliary cells and, together with the observation that K19CreERT/+; KrasLSL-G12D;
Ptenflox/flox mice gave rise to pre-malignant papillary ductal lesions in periportal areas, these findings
suggest that CCA arises from cholangiocytes in these models. In support of these results, a similar GEM
model was recently published by Lin et al., in which most of the previous findings are mirrored [43].
4.4. Mutations in the IDH Genes
Mutations in IDH1 and 2 genes occur in approximately 20% of human CCAs [61,62].
While wild-type IDH is part of the TCA cycle and converts isocitrate to α-Ketoglutarate, mutant IDH
acquires a neomorphic enzyme activity that results in the aberrant production of 2 Hydroxyglutarate
(2-HG) fromα-Ketoglutarate. Intracellular accumulation of 2-HG blocks hepatocyte lineage progression
and inhibits multiple enzymes that utilize α-Ketoglutarate as a co-enzyme and are involved in
epigenetic regulation [63]. In 2014, Saha et al. developed latent mutant Idh2 (Idh2LSL-R172K) mice
that were bred to the KrasLSL-G12D and Alb-Cre strains to determine the impact of IDH mutations on
cholangiocarcinogenesis in the context of mutant Kras. Multifocal liver masses resembling iCCA
that exhibited invasive growth patterns and metastatic potential formed in mice ranging from 33 to
58 weeks of age. Oval cell expansion and the presence of biliary intraepithelial neoplasia-like lesions
adjacent to tumor foci suggested that the tumors might evolve from such preceding preneoplastic
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stages [48]. Recently, positive phase III data for CCA patients harboring IDH mutations were reported
for the IDH inhibitor ivosidenib, emphasizing the direct relevance of such preclinical platforms for
“co-clinical trials” to establish mechanisms and biomarkers of response and resistance to the molecularly
targeted inhibitors.
4.5. Activation of the Notch Pathway
Conceptually similar to the HTVI models mentioned above, Zender et al. investigated the
influence of the NOTCH pathway in CCA development using a GEM model. When NICD was
expressed under the regulation of Alb-Cre, initial features of malignant transformations were present
within the liver by the age of 8 months and gave rise to iCCA-like tumors upon transplantation of
primary tissues into recipient mice [49]. In contrast, in the HTVI-based NICD overexpression model,
tumors formed 20 weeks after introduction of the transgene [12]. The reduced tumor latency might in
part be attributable to different levels of transgene expression, an alternate “cell of origin” targeted
with the oncogenic driver, as well as strain differences.
4.6. Mitochondrial Dysfunction
Mitochondrial dysfunction leads to increased ROS levels and severe liver injury. In a model
developed by Yuan et al., this inflammatory environment was induced by the disruption of mitochondrial
protein homeostasis in Hspd1flox/flox mice crossed to the Alb-Cre strain. Within the severely damaged liver,
focal areas of regenerating hepatocytes and cholangiocytes emerged, the latter showing resemblance
to human biliary intraepithelial neoplasia. The transgenic animals succumbed to severe liver injury
prior to development of fully established iCCA. However, transplantation of liver tissues gave rise to
transplantable tumors that histologically showed CCA features.
Notably, most of the regenerating foci observed in the primary livers retained Hspd1 expression,
indicating that the lesions evolved in the presence of the injured microenvironment but not through
cell-autonomous effects resulting from Hspd1 deletion. Indeed, the authors show that the biliary
reaction is the consequence of a Jnk-mediated response to Tumor necrosis factor released from
Kupffer cells, triggered by hepatic mitochondrial dysfunction and oxidative stress. While this model
does not allow for long-term experiments, due to the premature death of the transgenic animals,
it uniquely highlights the fundamental role of the microenvironment in the setting of chronic liver injury,
to create a “pre-carcinogenic niche” that promotes tumor development. The non-cell autonomous
mechanism that characterizes the development of CCA-precursor lesions in this model contrasts with
the cell-autonomous effects primarily involved in oncogene-driven GEM models.
4.7. Carcinogen-Treated GEMModels
Administration of carcinogens partially mimics the consequences of an inflammatory environment,
a frequent underlying risk factor in the development of human CCA. Integrating carcinogen-induced
liver injury and genetically “sensitized” murine models, Farazi et al. combined genetic deletion of
Tp53 with administration of the biliary toxin CCL4. In this model, iCCAs developed in the setting
of a fibro-inflammatory microenvironment with 50% penetrance in Tp53−/− mice and with 18% in
heterozygous Tp53+/− mice [57].
A decade later, Guest et al. found that administration of the hepatocarcinogen thioacetamide
(TAA) to mice lacking Tp53 in the cholangiocyte compartment, led to the development of iCCA
with long latency (>26 weeks) and incomplete penetrance [56]. It is highly likely that co-treatment
with carcinogens would also accelerate tumorigenesis in related genetic models of CCA, potentially
allowing for a dose-dependent titration of tumor development and a more faithful recapitulation
of the pro-inflammatory microenvironment that is considered to influence tumor pathobiology and
treatment response.
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4.8. Extrahepatic CCA
So far, the different GEM models described above are models of iCCA. In 2017, Nakagawa et al.
described the first GEM model of eCCA. Although the K19CreERT mouse strain achieves similar
recombination efficiencies across the different portions of the biliary tree, activation of the Kras
oncogene and concomitant deletion of the Tgfβr2 and Cdh1 (E-cadherin) in adult K19 positive cells
led to CCA development predominantly in the extrahepatic and perihilar bile ducts. The authors
provide evidence that the peribiliary glands, located within the walls of the extrahepatic bile ducts,
are the site of malignant transformation in this model, resulting in early-onset aggressive tumors
metastatic to the regional lymph nodes. Interestingly, the authors show that IL-33, likely released from
dying cholangiocytes due to E-cadherin loss, exerts a pro-proliferative stimulus on biliary epithelial
cells, thereby actively contributing to malignant transformation. Since K19CreERT is active in the
liver and in the lung, most animals die within 4 weeks after tamoxifen administration, due to liver
and/or respiratory failure. Therefore, the model is not suitable for long-term experiments. However,
the authors show that some of the crucial features of the model can be recapitulated and further
followed up using organoids derived from the multiallelic mice [52].
This study highlights how the proper combination of genetic alterations can guide CCA
development towards distinct disease subtypes. In conjunction with the Hspdflox/flox model of
iCCA, these findings further illustrate how genetic events can profoundly influence the surrounding
microenvironment to create a pro-inflammatory context that, in turn, exerts deleterious effects on the
epithelial liver cells.
5. Allograft Models
As an alternative to conventional GEM models, implantation of pre-malignant liver cell populations
into recipient mice emerged as a time-efficient approach that circumvents complex and time-consuming
breeding schemes.
5.1. Liver Implantation of Liver Progenitor Cells (LPCs)
In 2013, we described an allograft CCA mouse model based on the orthotopic implantation
of fetal LPCs isolated from Alb-Cre; KrasLSL-G12D; Tp53LSL-R172H/flox mice, resulting in the death of
recipient animals approximately 3 months after inoculation. Fetal liver cells can be easily further
genetically modified, for example through the introduction of retroviral vectors that overexpress
oncogene-encoding cDNA cassettes or encode for shRNAs to mimic TSG loss by RNA interference [53].
5.2. Liver Implantations of CCA Organoids
Recently, liver organoid technology has evolved as a novel system to model hepatobiliary
malignancies [54]. In contrast to LPCs, murine adult liver-derived three-dimensional (3D) organoids
can be propagated long-term in vitro and used on-demand, thereby abrogating the need for repetitive
isolations of primary cells, while retaining the genetic flexibility of the LPC approach. Organoids can
be rapidly engineered using various gene-editing strategies, and transplantation into the livers of
syngeneic mice enables tumor growth in an autochthonous and immune-competent microenvironment.
Notably, both LPCs and liver organoids retain their plasticity to give rise to both CCA and HCC-like
tumors, depending on the genetic context.
6. Cell Plasticity Leading to CCA: Evidence from Mouse Models
The lineage tracing approach to identify the cell of origin of a given cancer has been extensively
utilized in the last decade [64,65]. This approach has been also successfully applied to CCA, with the
purpose of unravelling whether these tumors arise from hepatic progenitor cells (HpSC), cholangiocytes,
or hepatocytes. Some of the landmark studies on this topic are summarized here. Specifically, a HpSC
origin of CCA was suggested in the AlbCre/N2ICD (Notch 2 intracellular domain) model treated with
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the hepatocarcinogen diethylnitrosamine (DEN) [66] as well as in mice overexpressing the active form
of Notch1 (AFP-NICD mice) [67]. However, the HpSC origin of CCA has been questioned by tracing
the thyroxine-binding globulin in mice subjected to diethylnitrosamine (DEN) and multiple injections
of CCl4 or TCPOBOP [68]. Similarly, using a cholangiocyte-lineage tracing system (CK19-lineage
tracing) to target p53 loss in biliary epithelia, it was found that the biliary epithelium is in fact the
specific target of transformation and origin of iCCA in this model [69]. Nonetheless, the mature
hepatocyte has also been identified as the cell of origin of CCA in lineage-tracing studies tracing
albumin [51] or transthyretin positive parenchyma cells [12]. In the latter study, the origin of CCA by
mature hepatocytes was further confirmed by electron microscopy findings.
The molecular mechanisms driving the transdifferentiation process in the liver, i.e., the capability of
a given cell type to convert into a different one, remain to be better elucidated in cholangiocarcinogenesis.
These mechanisms presumably implicate the involvement of multiple genetic and epigenetic events,
ultimately leading to the activation and interplay of several signaling pathways. Emerging evidence
implies a crucial role of the Hippo and Notch pathways in the hepatocyte-to-malignant cholangiocyte
conversion [11,12,14,18,51]. In particular, it has been shown that iCCA developing in AKT and
Yap co-expressing mice derive from mature hepatocyte, and this process is strictly dependent
on the canonical Notch2 signaling cascade [13]. Indeed, deletion of Notch2 in AKT/Yap-induced
tumors switched the phenotype from iCCA to hepatocellular lesions (adenomas or HCC). In contrast,
inactivation of Notch1 in hepatocytes did not lead to any significant histomorphological modification
of the original lesions (iCCA) in this model, identifying Notch2 as the major determinant of
hepatocyte-derived iCCA [69]. Obviously, further studies are necessary for a better understanding of
the transdifferentiation process in CCA.
Although the summarized data are highly helpful to identify the cell of origin of CCA and, thus,
to better elucidate the role(s) of the different cell types in cholangiocarcinogenesis, their relevance for
the human disease remains to be addressed. Presumably, as shown by the various experimental models,
the cell of origin of human CCA may also vary, depending on the oncogenes involved, the type, degree
and duration of the pro-oncogenic insults, the status of the liver, etc. In support of this hypothesis,
it is worthwhile to mention a paper by Holczbauer et al. [60]. In this study, the authors found that,
irrespective of origin, HpSc, lineage-committed hepatoblasts, and differentiated adult hepatocytes
transduced with transgenes encoding oncogenic H-Ras and SV40LT acquired markers of stemness,
side populations, and self-renewal capacity in vitro. In addition, these transduced cells were also able
to form a wide spectrum of liver tumors in vivo, such as CCA and hepatocellular carcinoma (HCC),
regardless of the cell of origin. Furthermore, the molecular profiles of each tumor subtype (CCA,
HCC, and undifferentiated/mesenchymal-like tumors) were highly similar irrespective of the cell of
origin, implying that potentially any cell type in the mouse hepatic lineage might undergo oncogenic
reprogramming into a “virtual” HpSC and drive development of CCA and/or other tumor types [60].
7. Summary
Genetic mouse models recapitulate many hallmarks of cholangiocarcinogenesis that cannot
be modeled using in vitro systems or, even, by xenotransplantation of human CCA cell lines or
patient-derived tissue (PDXs) into immunodeficient mice, two alternative in vivo models that have
been the focus of comprehensive reviews elsewhere [70,71]. Table 3 highlights the main features of
the different in vivo approaches and is intended for the selection of the most adequate model for each
study. A particular drawback of any mouse model is the intrinsically high cost of in vivo experiments
due to mice number per study, husbandry and maintenance. This issue becomes especially critical in
the case of GEM, where breeding schemes can be lengthy, or in those genetic models where tumor
latency is significantly longer than in graft models (>two months).
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Table 3. Advantages and disadvantages of in vivo mouse models. Features were rate from best (+++)
to worst (−). NA: not available for assessment.
Mouse Model Somatic GeneTransfer GEM
Implantation
of Mouse Cells
CCA Cells-Based
Xenografts
Patient-Derived
Xenografts
Time for tumor
development ++ ± +++ +++ +
Resource consumption + ± ++ ++ +
Technical training ± ++ ++ ++ ±
Ease of maintenance +++ + +++ +++ ±
Success rate of initiation +++ +++ +++ ++ +
Retention of phenotypic
features ++ +++ ++ ± +
Retention of genetic
features +++ +++ +++ ++ +++
Representation of genetic
spectrum ++ +++ ++ ++ +
Amenable to genetic
modification ++ ++ +++ +++ +
Physiological expression
of transgene ± +++ ++ ++ ++
Matched normal controls +++ +++ + − ±
Representation of early
stages of carcinogenesis + +++ + − −
Cell of origin + ++ +++ − −
Tumor progression +++ +++ +++ ++ ++
Tumor-stroma interactions ++ +++ ++ ± +
Immune
microenvironment ++ +++ ++ − ±
Chemo-/targeted therapies
studies +++ +++ +++ ++ +++
Immuno-Oncology studies ++ +++ +++ − +
A key advantage of genetic mouse models over human cell/tissue-xenografted mouse models,
however, is the suitability of murine models to investigate tumor development and tumor-stroma
crosstalk within the context of an immunocompetent microenvironment. In traditional transgenic
approaches, tumor development can be followed through gradual changes within the epithelial tumor
cell compartment, along with a remodeling of the surrounding stroma, thereby allowing researchers to
also investigate the early processes of iCCA development within an otherwise intact microenvironment.
This “stepwise” tumorigenesis may be only incompletely mirrored in somatic gene transfer and murine
allograft model systems. However, these models bear the genetic flexibility to rapidly incorporate
additional genetic alterations to functionally annotate potential cancer driver genes in vivo and to
characterize them not only regarding their transformative potential, but also concerning their effects
on the tumor microenvironment. Furthermore, several models also depend on the consequences of an
inflammatory stimulus on tumorigenesis that is derived from the microenvironment itself.
Clearly, no single model will be capable to adequately address all the questions related to
cholangiocarcinogenesis. Although the models developed thus far have considerably helped us to
better understand important aspects of cholangiocarcinogenesis, at the same time, they have also
clearly demonstrated how complex liver tumor formation is. For instance, several of the models
can give rise to the full spectrum of liver cancer, from CCA to HCC to mixed tumors. In some of
the models, those differences can be traced back to certain engineered genetic alterations within the
epithelial tumor cell compartment, to gene dosage, and to microenvironmental cues that influence the
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determination of liver tumorigenesis into biliary or hepatocyte cell lineage differentiation. Similarly,
allograft models using primary liver progenitors or organoids can also be directed towards the different
lineages of primary liver cancers, depending on the respective cancer drives. When these models are
taken seriously, one has to acknowledge that a “dogmatic” approach that tries to establish that “one
cell of origin” for CCA may be a misguiding simplification of highly complex mechanisms that guide
cellular transdifferentiation and/or neoplastic transformation in the course of liver tumor development.
While the observations that some models lead, in part, to tumors of hepatocellular or mixed
differentiation suggests an avenue to their applicability towards understanding tumor “lineage”
differentiation, it also indicates how important a thorough a priori characterization of these model
systems is in order to adequately use them in translational research. Considering the devastating
prognosis and the lack of durable responses, we need accurate pre-clinical systems that can recapitulate
the challenges encountered when CCA patients are treated in clinical practice; although effective in
selected patient subgroups, precision oncology is hampered by early relapse or insufficient response,
despite the presence of targetable genetic lesions. Genetically flexible model systems have the potential
to help us to improve our understanding of primary and secondary resistance mechanisms that
influence the response to targeted therapies. In addition, these immune-competent in vivo systems
may also help us to understand why immune-oncology approaches have thus far failed in CCA and
guide us in the implementation of novel therapeutic concepts.
8. Concluding Remarks
Although the development of an ideal mouse model for the study of CCA is unrealistic, in part due
to the genetic and histological complexity of this tumor, to date, the spectrum of genetic mouse models
offers the research community an unprecedented opportunity to elucidate CCA pathophysiology.
Currently, the therapeutic portfolio for CCA patients is finally starting to expand considerably: precision
medicine is on the verge of becoming an integral component of CCA treatment, and immune-oncology
approaches are actively pursued. This development emphasizes the need for immune-proficient,
translational model systems in which cancer cell intrinsic and extrinsic mechanisms can be adequately
addressed. Based on insights from current clinical trials and integrative molecular profiling studies
that imply the existence of several molecular CCA subgroups, it is likely that, within the coming years,
the repertory of genetic mouse models will further expand. Building on the “groundwork” that has
been laid by the existing approaches, more diversified in vivo systems will be developed, and serve as
pre-clinical platforms to address the prevailing questions, from the characterization of the initial steps
during cholangiocarcinogenesis, the dissection of histopathological and molecular features, to response
and resistance to novel therapeutics.
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